Loading company…
Seaport Therapeutics develops clinical-stage medicines for neuropsychiatric conditions.
Seaport's Glyph platform is designed to improve oral bioavailability and address adverse effects associated with some medicines. Its programs target conditions including major depression with anxiety and generalized anxiety disorder. Founded in 2024 and based in Boston, it trades on Nasdaq under SPTX.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in